[1]王 玮,王 伟,李婷婷.晚期结直肠癌患者血清微小RNA-199b和微小RNA-203水平检测及其预后预测价值分析[J].陕西医学杂志,2024,(6):832-837.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.024]
 WANG Wei,WANG Wei,LI Tingting.Detection and prognostic value of serum microRNA-199b and microRNA-203 levels in patients with advanced colorectal cancer[J].,2024,(6):832-837.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.024]
点击复制

晚期结直肠癌患者血清微小RNA-199b和微小RNA-203水平检测及其预后预测价值分析

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年6期
页码:
832-837
栏目:
临床检验
出版日期:
2024-06-05

文章信息/Info

Title:
Detection and prognostic value of serum microRNA-199b and microRNA-203 levels in patients with advanced colorectal cancer
作者:
王 玮王 伟李婷婷
(淮安市淮安医院肿瘤内科,江苏 淮安 223200)
Author(s):
WANG WeiWANG WeiLI Tingting
(Department of Oncology,Huai'an Huai'an Hospital,Huai'an 223200,China)
关键词:
结直肠癌 晚期 微小RNA-199b 微小RNA-203 预后 生存曲线
Keywords:
Colorectal cancer Late stage microRNA-199b microRNA-203 Prognosis Curve of survival
分类号:
R 735.35
DOI:
DOI:10.3969/j.issn.1000-7377.2024.06.024
文献标志码:
A
摘要:
目的:检测晚期结直肠癌患者血清微小RNA(miR)-199b和miR-203水平,分析其对患者预后的预测价值。方法:选择Ⅳ期结直肠癌患者92例为结直肠癌组,选择结直肠炎患者92例为对照组。采用逆转录聚合酶链式反应检测两组血清miR-199b及miR-203水平并进行比较。根据结直肠癌患者12个月随访结果分为病死组和生存组,分析晚期结直肠癌患者预后的影响因素,评价血清miR-199b及miR-203对晚期结直肠癌患者预后的预测价值,并进行生存分析。结果:结直肠癌组血清miR-199b、miR-203低于对照组(均P<0.05)。92例Ⅳ期结直肠癌患者中病死36例,纳入病死组,其余患者纳入生存组。病死组血清基质金属蛋白酶-14(MMP-14)、趋化因子受体4(CXCR4)水平高于生存组,血清miR-199b、miR-203低于生存组(均P<0.05)。MMP-14和CXCR4是晚期结直肠癌患者病死的风险因素,miR-199b和miR-203是晚期结直肠癌患者病死的保护因素(均P<0.05)。miR-199b与MMP-14、CXCR4呈负相关(r=-0.403、-0.458,均P<0.05),miR-203与MMP-14、CXCR4呈负相关(r=-0.461、-0.479,均P<0.05)。血清miR-199b、miR-203对晚期结直肠癌患者病死均有一定预测价值,且两项联合优于单项(均P<0.05)。血清miR-199b和miR-203高表达组生存率高于低表达组(均P<0.05)。结论:晚期结直肠癌患者血清miR-199b、miR-203水平降低,对患者预后具有良好的预测价值,且两项联合预测价值更高。
Abstract:
Objective:To detect serum microRNA(miR)-199b and miR-203 levels in patients with advanced colorectal cancer,and to evaluate their prognostic value.Methods:Ninety-two patients with stage Ⅳ colorectal cancer were selected as the colorectal cancer group,and 92 patients with colorectal inflammation were selected as the control group.The serum levels of miR-199b and miR-203 in the two groups were detected by reverse transcription polymerase chain reaction and compared.According to the 12-month follow-up results of patients with colorectal cancer,they were divided into death group and survival group,and the prognostic factors of patients with advanced colorectal cancer were analyzed,and the predictive value of serum miR-199b and miR-203 for the prognosis of patients with advanced colorectal cancer was evaluated,and survival analysis was performed.Results: The serum levels of miR-199b and miR-203 in the colorectal cancer group were lower than those in the control group(all P<0.05).Among the 92 patients with stage Ⅳ colorectal cancer,36 patients died and the rest were enrolled in the death group and the survival group,respectively.The serum levels of MMP-14 and CXCR4 in the death group were higher than those in the survival group,and the serum levels of miR-199b and miR-203 were lower than those in the survival group(all P<0.05).MMP-14 and CXCR4 were risk factors for the death of patients with advanced colorectal cancer,and miR-199b and miR-203 were protective factors for the death of patients with advanced colorectal cancer(all P<0.05).MiR-199b was negatively correlated with MMP-14 and CXCR4(r=-0.403,-0.458,all P<0.05),miR-203 was negatively correlated with MMP-14 and CXCR4(r=-0.461,-0.479,all P<0.05).Serum miR-199b and miR-203 had certain predictive value for the death of patients with advanced colorectal cancer,and the combination of the two was better than the single one(all P<0.05).The survival rate of serum miR-199b and miR-203 high expression group was higher than that of low expression group(all P<0.05).Conclusion:The serum levels of miR-199b and miR-203 are decreased in patients with advanced colorectal cancer,which have good predictive value for the prognosis of patients,and the combination of the two has a higher predictive value.

参考文献/References:

[1] 郑佳露,郑金洲,顾贤.藤龙补中汤联合化疗治疗晚期结直肠癌疗效研究[J].陕西中医,2023,44(8):1042-1046.
[2] AKDENIZ N,KAPLAN M A,UNCU D,et al.The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer:A multicenter study[J].Int J Colorectal Dis,2021,36(6):1311-1319.
[3] TOURNIGAND C,ANDRE T,ACHILLE E,et al.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:A randomized GERCOR study[J].J Clin Oncol,2023,41(19):3469-3477.
[4] MARTINEZ-ILLESCAS N G,LEAL S,GONZALEZ P,et al.MiR-203 drives breast cancer cell differentiation[J].Breast Cancer Res,2023,25(1):91.
[5] CUI X,TIAN Y,ZHAO Y,et al.MiR-199b-5p-AKAP1-DRP1 pathway plays a key role in ox-LDL-induced mitochondrial fission and endothelial apoptosis[J].Curr Pharm Biotechnol,2022,23(13):1612-1622.
[6] HOCHBERG J T,SOHAL A,HANDA P,et al.Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid[J].JHEP Rep,2023,5(6):100729.
[7] SALEM S,MOSAAD R.Crosstalk between miR-203 and PKCtheta regulates breast cancer stem cell markers[J].Ann Hum Genet,2021,85(3-4):105-114.
[8] 中华人民共和国国家卫生健康委员会.中国结直肠癌诊疗规范(2020版)[J].中华消化外科杂志,2020,19(6):563-588.
[9] 胡旭昊,孟昆,狄茂军.结直肠癌患者手术前后淋巴细胞与单核细胞比值动态变化及其对预后的预测价值[J].陕西医学杂志,2023,52(6):719-722,727.
[10] 王敬东,张庆尧.Mfolfox6方案联合西妥昔单抗和辛伐他汀治疗K-Ras突变结直肠癌疗效及对预后的影响[J].陕西医学杂志,2022,51(10):1290-1293.
[11] 章玲艳,吴会晨,汪飞,等.参苓白术散加减对结直肠癌患者化疗后骨髓抑制和免疫功能的影响[J].陕西中医,2023,44(8):1086-1089.
[12] LIU K,DOU R,YANG C,et al.Exosome-transmitted miR-29a induces colorectal cancer metastasis by destroying the vascular endothelial barrier[J].Carcinogenesis,2023,44(4):356-367.
[13] HUANG Z,KALLER M,HERMEKING H.CRISPR/Cas9-mediated inactivation of miR-34a and miR-34b/c in HCT116 colorectal cancer cells:Comprehensive characterization after exposure to 5-FU reveals EMT and autophagy as key processes regulated by miR-34[J].Cell Death Differ,2023,30(8):2017-2034.
[14] GHONBALANI Z N,SHAHMOHAMADNEJAD S,PASALAR P,et al.Hypermethylated miR-424 in colorectal cancer subsequently upregulates VEGF[J].J Gastrointest Cancer,2022,53(2):380-386.
[15] DOU R,LIU K,YANG C,et al.EMT-cancer cells-derived exosomal miR-27b-3p promotes circulating tumour cells-mediated metastasis by modulating vascular permeability in colorectal cancer[J].Clin Transl Med,2021,11(12):e595.
[16] JIA Q,LIAO X,XU B,et al.MiR-128-1-5p inhibits cell proliferation and induces cell apoptosis via targeting PRKCQ in colorectal cancer[J].Cancer Biol Ther,2023,24(1):2226421.
[17] LI F,ZHANG M,YIN X,et al.Exosomes-derived miR-548am-5p promotes colorectal cancer progression[J].Cell Mol Biol(Noisy-le-grand),2023,69(12):104-110.
[18] CHEN Q,DENG Q,PAN Y,et al.Hypoxia-induced miR-653 enhances colorectal cancer progression by targeting circSETD3/KLF6 axis[J].J Cancer,2023,14(1):163-173.
[19] HONG S A,LEE S,PARK J,et al.MiR-199a and miR-199b facilitate diffuse gastric cancer progression by targeting frizzled-6[J].Sci Rep,2023,13(1):17480.
[20] TAN B,GUO J,WANG L,et al.Expression and change of miR-199b-5p,sHLA-G in thyroid carcinoma[J].Exp Mol Pathol,2021,120(1):104643.
[21] MAO Z,LIU R,ZHANG M,et al.Prognostic and clinicopathological value of miR-199b in cancers:A meta-analysis[J].Biomark Med,2022,16(11):879-888.
[22] WANG S L,DONG X W,ZHAO F,et al.MiR-203 inhibits cell proliferation,invasion,and migration of ovarian cancer through regulating RGS17[J].J Biol Regul Homeost Agents,2021,35(3):1109-1115.
[23] ZHAO H,MING T,TANG S,et al.Wnt signaling in colorectal cancer:Pathogenic role and therapeutic target[J].Mol Cancer,2022,21(1):144.
[24] AGARWAL S,AFAQ F,BAJPAI P,et al.DCZ0415,a small-molecule inhibitor targeting TRIP13,inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/beta-catenin pathway in colorectal cancer[J].Mol Oncol,2022,16(8):1728-1745.
[25] ZHU D,QI H,ZHU H.Hsa-miR-199b-3p suppresses osteosarcoma progression by targeting CCDC88A,inhibiting epithelial-to-mesenchymal transition,and Wnt/beta-catenin signaling pathway[J].Sci Rep,2023,13(1):12544.
[26] LI J,CHEN C H,O'NEILL K L,et al.Combined inhibition of aurora kinases and Bcl-xL induces apoptosis through select BH3-only proteins[J].J Biol Chem,2023,299(2):102875.
[27] JAIN S M,DEKA D,DAS A,et al.Role of interleukins in inflammation-mediated tumor immune microenvironment modulation in colorectal cancer pathogenesis[J].Dig Dis Sci,2023,68(8):3220-3236.
[28] STEHR A M,WANG G,DEMMLER R,et al.Neutrophil extracellular traps drive epithelial-mesenchymal transition of human colon cancer[J].J Pathol,2022,256(4):455-467.
[29] BABULA A,GALUSZKA-BULAGA A,WEGLARCZYK K,et al.CD44-hyaluronan axis plays a role in the interactions between colon cancer-derived extracellular vesicles and human monocytes[J].Oncol Lett,2023,26(3):413.
[30] HISAMORI S,MUKOHYAMA J,KOUL S,et al.Upregulation of BMI1-suppressor miRNAs(miR-200c,miR-203)during terminal differentiation of colon epithelial cells[J].J Gastroenterol,2022,57(6):407-422.
[31] 燕普,常小伟,张永康.FOXO3联合XPNPEP2和MMP-14对结直肠癌不良预后的预测分析[J].中国肿瘤临床与康复,2021,28(10):1169-1172.
[32] 邓芳,王强.结直肠癌CXCL12-CXCR4/CXCR7轴作用机制研究进展[J].中华肿瘤防治杂志,2022,29(23):1709-1714.

相似文献/References:

[1]柯东平,毛俊倩,刘 琪,等.TRIM21调控人结直肠癌细胞增殖分子机制研究*[J].陕西医学杂志,2019,(6):691.
 KE Dongping,MAO Junqian,LIU Qi,et al.Study on molecular mechanisms of TRIM21 in regulating proliferation of colorectal cancer[J].,2019,(6):691.
[2]张 慧,陈景志,陈建立△,等.DCC和MKK4基因在结直肠癌组织中的表达及临床意义*[J].陕西医学杂志,2019,(8):968.
 ZHANG Hui,CHEN Jingzhi,CHEN Jianli,et al.Expression and clinical significance of DDC and MKK4 genes in colorectal cancer tissue[J].,2019,(6):968.
[3]高怀军,余 伟.腹腔镜结直肠癌根治术治疗结直肠癌临床疗效及对患者胃肠功能的影响[J].陕西医学杂志,2019,(8):990.
 GAO Huaijun,YU Wei..Clinical study of laparoscopic radical resection in the treatment of colorectal cancer in and its influence on gastrointestinal function[J].,2019,(6):990.
[4]赵英旋,白玉勤.结直肠癌患者肿瘤出芽情况与临床病理特征、程序性死亡受体1及程序性死亡配体1表达相关性研究[J].陕西医学杂志,2021,50(6):747.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.027]
 ZHAO Yingxuan,BAI Yuqin.Correlation between tumor budding and clinicopathological characteristics,expression of PD-1 and PD-L1 in CRC[J].,2021,50(6):747.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.027]
[5]马 骞,朱 军,蔡梦珊,等.基于exoRBase外泌体数据库结直肠癌竞争性内源RNA网络构建及富集分析[J].陕西医学杂志,2021,50(7):797.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.007]
 MA Qian,ZHU Jun,CAI Mengshan,et al.Construction and enrichment analysis of competing endogenous RNA network for colorectal cancer based on the exoRBase database[J].,2021,50(6):797.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.007]
[6]章玉玲,周 岳.结直肠癌患者血清循环肿瘤细胞、糖类抗原24-2、糖类抗原19-9水平及其与临床病理特征关系[J].陕西医学杂志,2022,51(3):322.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.013]
 ZHANG Yuling,ZHOU Yue.Serum circulating tumor cells,carbohydrate antigen 24-2 and carbohydrate antigen 19-9 levels in patients with colorectal cancer and their relationship with clinicopathological features[J].,2022,51(6):322.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.013]
[7]张利伟,胡海燕.粪便硫酸类肝素蛋白多糖2与分泌型卷曲相关蛋白2基因甲基化检测在结直肠癌筛查中的应用价值[J].陕西医学杂志,2022,51(3):366.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.024]
 ZHANG Liwei,HU Haiyan.Application value of feces detection of syndecan-2 and secreted frizzled related protein 2 gene methylation in colorectal cancer screening[J].,2022,51(6):366.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.024]
[8]曹巍巍,郭修田.结直肠癌原位移植造模技术研究进展[J].陕西医学杂志,2022,51(6):764.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.029]
 CAO Weiwei,GUO Xiutian.Research progress of orthotopic transplantation technology for colorectal cancer[J].,2022,51(6):764.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.029]
[9]张言言,韩 刚,曹 羽,等.同源盒基因10调控胰岛素样生长因子结合蛋白3与肠癌细胞5-氟尿嘧啶抵抗的关系研究[J].陕西医学杂志,2022,51(7):771.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.001]
 ZHANG Yanyan,HAN Gang,CAO Yu,et al.Relationship between regulation of IGFBP3 by HOXD10 and 5-fluorouracil resistance in colorectal cancer cells[J].,2022,51(6):771.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.001]
[10]张晓峰,冯 景,季飞燕,等.结直肠癌术后辅助化疗患者肠内营养不耐受影响因素及小野寺预后营养指数预测价值分析[J].陕西医学杂志,2022,51(9):1114.[doi:DOI:10.3969/j.issn.1000-7377.2022.09.016]

备注/Memo

备注/Memo:
基金项目:江苏省自然科学基金资助面上项目(BK20201183)
更新日期/Last Update: 2024-06-05